C:\STNEXP4\QUERIES\10075654.str





chain nodes :
16 17 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
10-16 17-20 17-21 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
exact/norm bonds :
4-7 5-10 7-8 7-11 8-9 8-13 9-10 10-16 11-12 12-13 17-20 17-21 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:C,N

G2:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 16:CLASS 17:CLASS 18:CLASS 20:CLASS 21:CLASS 22:Atom

```
=>
Uploading 10075654.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,N
G2 O,S,N

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:59:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    559 TO ITERATE

100.0% PROCESSED     559 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         9762 TO    12598
PROJECTED ANSWERS:               1 TO       80

L2             1 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 18:59:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  11091 TO ITERATE

100.0% PROCESSED   11091 ITERATIONS                         28 ANSWERS
SEARCH TIME: 00.00.01

L3            28 SEA SSS FUL L1

=> s l3
L4             2 L3
```

=> d l4 1-2 bib,ab,hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637681 CAPLUS
DN 137:185503
TI Triazolopyrimidinones as MMP inhibitors
IN Andrianjara, Charles; Jacobelli, Henry; Gaudilliere, Bernard; Breuzard, Francine
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064595	A1	20020822	WO 2002-EP1961	20020211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002151558	A1	20021017	US 2002-75654	20020214
PRAI	US 2001-268757P	P	20010214	← Appl. Prov. Priority.	

OS MARPAT 137:185503
AB Title compds. I [W, X = N, (un)substituted CH; Y = O, S, NH, N-alkyl; Z = O, S, (un)substituted NH, CH2; Z1 = (un)substituted CH2; n = 0-8; R = (un)substituted 5-6-membered ring, bicyclic ring system, optionally contg. 1-4 N, O, and/or S atoms; R1 = H, (un)substituted alkyl, alkenyl, alkynyl] and their N-oxides were prepd.for use as specific inhibitors of type-13 matrix metalloprotease. Thus, 4-benzyl-7-bromo-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one was converted to the nitrile, hydrolyzed to the acid and esterified to give the benzyl ester which had an IC50 for inhibition of MMP-13 of 0.0034 .mu.M.
IT **449211-02-3P 449211-03-4P 449211-05-6P**
449211-06-7P 449211-07-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of triazolopyrimidinones as MMP inhibitors)
RN 449211-02-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxylic acid, 4,5-dihydro-5-oxo-4-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449211-03-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxylic acid, 4,5-dihydro-5-oxo-4-(phenylmethyl)-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 449211-05-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4,5-dihydro-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-06-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-4-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-07-8 CAPLUS
CN Imidazo[1,2-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4,5-dihydro-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **449211-43-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of triazolopyrimidinones as MMP inhibitors)
RN 449211-43-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-3,5-dihydro-5-oxo- (9CI) (CA INDEX NAME)



IT **449211-15-8P 449211-17-0P 449211-19-2P**
449211-20-5P 449211-21-6P 449211-24-9P
449211-27-2P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of triazolopyrimidinones as MMP inhibitors)

RN 449211-15-8 CAPLUS
CN Benzoic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-17-0 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-19-2 CAPLUS
CN Benzoic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triaz

olo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-20-5 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 449211-21-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4,5-dihydro-N-[(4-methoxyphenyl)methyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 449211-24-9 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-27-2 CAPLUS
CN Benzeneacetic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **449211-09-0P 449211-10-3P 449211-11-4P**
449211-13-6P 449211-22-7P 449211-25-0P
449211-28-3P 449211-29-4P 449211-30-7P
449211-31-8P 449211-32-9P 449211-33-0P
449211-34-1P 449211-35-2P 449211-36-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of triazolopyrimidinones as MMP inhibitors)

RN 449211-09-0 CAPLUS

CN Imidazo[1,2-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-4-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-10-3 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-N-[(4-methoxyphenyl)methyl]-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-11-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-4-(phenylmethyl)-N-[3-(4-pyridinylthio)propyl]- (9CI) (CA INDEX NAME)



RN 449211-13-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[(4-cyanophenyl)methyl]-4,5-dihydro-5-oxo- (9CI) (CA INDEX NAME)



RN 449211-22-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4-[(4-cyanophenyl)methyl]-4,5-dihydro-5-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-25-0 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-28-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-N-(4-pyridinylmethyl)-4-[3-(4-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 449211-29-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4-[2-(4-chlorophenoxy)ethyl]-4,5-dihydro-N-[(4-methoxyphenyl)methyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 449211-30-7 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-31-8 CAPLUS
CN Benzoic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-32-9 CAPLUS
CN Benzoic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-33-0 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-34-1 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-35-2 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-36-3 CAPLUS
CN Benzeneacetic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637472 CAPLUS
DN 137:201321
TI Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors
IN Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory; Roark, William Howard
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064080	A2	20020822	WO 2002-IB447	20020213
WO 2002064080	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003078276	A1	20030424	US 2002-75069	20020213
PRAI US 2001-268821P	P	20010214		

AB Title compds., I [R1 and R2 together may form a substituted arom. ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and II [R5, R6 = arylalkylamine, heterocyclylalkoxy, etc.; R7 = H, MeO, NO2, etc.], are prepd. and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepd. in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC50 value (in .mu.M) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

IT **449211-43-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix

metalloproteinase inhibitors)

RN 449211-43-2 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-3,5-dihydro-5-oxo- (9CI) (CA INDEX NAME)



IT **449211-17-0P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compd.; prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449211-17-0 CAPLUS

CN Benzoic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **449211-02-3P 449211-03-4P 449211-05-6P**
449211-06-7P 449211-07-8P 449211-09-0P
449211-10-3P 449211-11-4P 449211-13-6P
449211-15-8P 449211-19-2P 449211-20-5P
449211-21-6P 449211-22-7P 449211-24-9P

449211-25-0P 449211-27-2P 449211-28-3P
449211-29-4P 449211-30-7P 449211-31-8P
449211-32-9P 449211-33-0P 449211-34-1P
449211-35-2P 449211-36-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449211-02-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxylic acid, 4,5-dihydro-5-oxo-4-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449211-03-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxylic acid, 4,5-dihydro-5-oxo-4-(phenylmethyl)-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 449211-05-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4,5-dihydro-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-06-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-4-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-07-8 CAPLUS
CN Imidazo[1,2-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4,5-dihydro-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-09-0 CAPLUS
CN Imidazo[1,2-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-4-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-10-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-N-[(4-methoxyphenyl)methyl]-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-11-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-4-(phenylmethyl)-N-[3-(4-pyridinylthio)propyl]- (9CI) (CA INDEX NAME)



RN 449211-13-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[(4-cyanophenyl)methyl]-4,5-dihydro-5-oxo- (9CI) (CA INDEX NAME)



RN 449211-15-8 CAPLUS
CN Benzoic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-19-2 CAPLUS
CN Benzoic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-20-5 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 449211-21-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4,5-dihydro-N-[(4-methoxyphenyl)methyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 449211-22-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4-[(4-cyanophenyl)methyl]-4,5-dihydro-5-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449211-24-9 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-25-0 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-27-2 CAPLUS
CN Benzeneacetic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449211-28-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4,5-dihydro-5-oxo-N-(4-pyridinylmethyl)-4-[3-(4-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 449211-29-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxamide, 4-[2-(4-chlorophenoxy)ethyl]-4,5-dihydro-N-[(4-methoxyphenyl)methyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 449211-30-7 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-31-8 CAPLUS
CN Benzoic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-32-9 CAPLUS
CN Benzoic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-33-0 CAPLUS
CN Benzoic acid, 4-[[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-34-1 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-35-2 CAPLUS
CN Benzeneacetic acid, 4-[[7-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449211-36-3 CAPLUS
CN Benzeneacetic acid, 4-[[5-oxo-7-[[(4-pyridinylmethyl)amino]carbonyl][1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 18:58:14 ON 15 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 18:58:40 ON 15 MAY 2003
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3             28 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:59:41 ON 15 MAY 2003
L4              2 S L3

     FILE 'CAOLD' ENTERED AT 19:00:04 ON 15 MAY 2003

=> s l3
L5              0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.40     158.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -1.30

STN INTERNATIONAL LOGOFF AT 19:00:13 ON 15 MAY 2003
```